[go: up one dir, main page]

FR16C0042I2 - Derives de composes heterocycliques et medicaments - Google Patents

Derives de composes heterocycliques et medicaments

Info

Publication number
FR16C0042I2
FR16C0042I2 FR16C0042C FR16C0042C FR16C0042I2 FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2 FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2
Authority
FR
France
Prior art keywords
drugs
derivatives
heterocyclic compounds
heterocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0042C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18978246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0042(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of FR16C0042I1 publication Critical patent/FR16C0042I1/fr
Application granted granted Critical
Publication of FR16C0042I2 publication Critical patent/FR16C0042I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
FR16C0042C 2001-04-26 2016-10-24 Derives de composes heterocycliques et medicaments Active FR16C0042I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001129765 2001-04-26
PCT/JP2002/004118 WO2002088084A1 (fr) 2001-04-26 2002-04-25 Derives de composes heterocycliques et medicaments

Publications (2)

Publication Number Publication Date
FR16C0042I1 FR16C0042I1 (fr) 2016-12-09
FR16C0042I2 true FR16C0042I2 (fr) 2017-03-17

Family

ID=18978246

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0042C Active FR16C0042I2 (fr) 2001-04-26 2016-10-24 Derives de composes heterocycliques et medicaments

Country Status (19)

Country Link
US (1) US7205302B2 (fr)
EP (1) EP1400518B1 (fr)
JP (1) JP4479152B2 (fr)
KR (1) KR100921760B1 (fr)
CN (1) CN1301973C (fr)
BE (1) BE2016C051I2 (fr)
BR (1) BRPI0209249B8 (fr)
CA (1) CA2445344C (fr)
DE (1) DE60217674T2 (fr)
DK (1) DK1400518T3 (fr)
ES (1) ES2276931T3 (fr)
FR (1) FR16C0042I2 (fr)
LU (1) LU93266I2 (fr)
MX (1) MXPA03009800A (fr)
NL (1) NL300836I2 (fr)
PT (1) PT1400518E (fr)
RU (1) RU2283835C3 (fr)
TW (1) TWI316055B (fr)
WO (1) WO2002088084A1 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1670460B1 (fr) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
FR2869224B1 (fr) * 2004-04-22 2006-06-09 Oreal Compose 2-oxy-acetamide, ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
JP2007533708A (ja) * 2004-04-22 2007-11-22 ロレアル ２−オキシ−アセトアミド化合物、ケラチン繊維増殖の刺激または誘導、および／または喪失を遅延させるためのその使用および組成物
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
ES2817557T3 (es) * 2008-02-28 2021-04-07 Nippon Shinyaku Co Ltd Inhibidor de fibrosis
EP2280696B9 (fr) 2008-03-18 2015-12-09 Arena Pharmaceuticals, Inc. Modulateurs du récepteur de la prostacycline (pgi2) utiles pour le traitement de troubles liés à celui-ci
WO2009154246A1 (fr) * 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
ES2557303T3 (es) * 2008-06-23 2016-01-25 Nippon Shinyaku Co., Ltd. Agente terapéutico para la estenosis del canal espinal
LT2289518T (lt) * 2008-06-23 2017-01-10 Nippon Shinyaku Co., Ltd. Terapinis agentas nuo uždegiminės žarnų ligos
WO2009157397A1 (fr) * 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
WO2010010909A1 (fr) * 2008-07-23 2010-01-28 東レ株式会社 Agent thérapeutique utilisé dans l’insuffisance rénale chronique
ES2652590T3 (es) * 2008-08-13 2018-02-05 Actelion Pharmaceuticals Ltd. Composiciones terapéuticas que contienen macitentan
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011024874A1 (fr) * 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
CN102655866B (zh) 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US8809525B2 (en) 2010-02-05 2014-08-19 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2816032A4 (fr) 2012-02-13 2015-09-30 Takeda Pharmaceutical Composé à noyaux aromatiques
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
CN103588598B (zh) * 2013-11-20 2015-06-17 苏州大学 一种制备2-烯醛衍生物的方法
CN104829465B (zh) * 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 一种4-异丙氨基-1-丁醇的制备方法
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (fr) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Selexipag amorphe et son procédé de préparation
CN106467496B (zh) * 2015-08-14 2020-12-08 苏州国匡医药科技有限公司 4-[(5,6-二苯基哌嗪-2-基)(异丙基)胺基]-1-丁醇的制备方法
US10188648B2 (en) 2015-09-03 2019-01-29 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042828A2 (fr) 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Procédé de préparation de sélexipag et intermédiaires de ce dernier
WO2017042731A1 (fr) 2015-09-10 2017-03-16 Lupin Limited Forme amorphe du sélexipag et dispersion solide associée
WO2017060827A1 (fr) 2015-10-07 2017-04-13 Lupin Limited Procédé amélioré pour la préparation de sélexipag ou de ses sels pharmaceutiquement acceptables
CN108289890B (zh) * 2015-12-02 2021-04-27 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
WO2017109772A1 (fr) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Forme amorphe du sélexipag
ES2991706T3 (es) 2015-12-23 2024-12-04 Commw Scient Ind Res Org Compuestos de enamina para protección contra radiación UV
EP3192502A1 (fr) 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag
US10815204B2 (en) * 2016-04-01 2020-10-27 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN107286104A (zh) * 2016-04-12 2017-10-24 常州方楠医药技术有限公司 一种赛乐西帕与药用辅料的固体分散体及其制备方法
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
WO2018008042A1 (fr) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Nouveau procédé de préparation de 2-{4-[(5,6-diphényl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(méthylsulfonyl)acétamide et nouveaux polymorphes associés
TW202413340A (zh) * 2016-07-12 2024-04-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
WO2018015974A1 (fr) 2016-07-20 2018-01-25 Mylan Laboratories Limited Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
WO2018015975A1 (fr) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Dispersion solide amorphe de selxipag.
WO2018022704A1 (fr) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Forme cristalline vi de selexipag
CA3030949A1 (fr) 2016-07-29 2018-02-01 Toray Industries, Inc. Derive de guanidine et son utilisation a des fins medicales
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
CN106316967B (zh) * 2016-08-19 2019-02-05 上海艾康睿医药科技有限公司 西里帕格中间体及西里帕格的制备方法
WO2018078383A1 (fr) 2016-10-27 2018-05-03 Cipla Limited Composition pharmaceutique comprenant du selexipag amorphe
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
CA3070805A1 (fr) 2017-07-27 2019-01-31 Allergan, Inc. Agonistes du recepteur de la prostacycline pour la reduction de la graisse corporelle
AR112842A1 (es) 2017-09-28 2019-12-18 Nippon Shinyaku Co Ltd Cristal de pirazina
MX2020004962A (es) 2017-11-16 2020-08-27 Nippon Shinyaku Co Ltd Preparacion de liberacion controlada.
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
WO2019154363A1 (fr) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 Agoniste du récepteur de la prostacycline
KR20200123447A (ko) 2018-02-21 2020-10-29 니뽄 신야쿠 가부시키가이샤 입상 조성물, 입상 조성물의 제조 방법, 및 입상 조성물의 용출성 개선 방법
CN108558653A (zh) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 赛乐西帕中间体及赛乐西帕的制备方法
CN108774183A (zh) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 一种乙二醇类化合物的制备方法
CN108863955B (zh) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
US12427145B2 (en) 2019-02-03 2025-09-30 Innovate Therapeutics Llc Controlled release pharmaceutical composition of Selexipag or it's active metabolite
EP3965767A1 (fr) 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Méthodes de traitement de l'hypertension pulmonaire associée à la sarcoïdose
US12419887B2 (en) 2019-05-21 2025-09-23 Actelion Pharmaceuticals Ltd. Transitioning patients treated for pulmonary arterial hypertension to selexipag
EP3982967A1 (fr) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Procédés de traitement de l'hypertension artérielle pulmonaire
AU2020333633A1 (en) * 2019-08-19 2022-03-17 Nippon Shinyaku Co., Ltd. Salt
PE20221455A1 (es) 2019-10-23 2022-09-21 Actelion Pharmaceuticals Ltd Composicion farmaceutica que comprende selexipag
BR112022010311A2 (pt) 2019-11-29 2022-08-16 Actelion Pharmaceuticals Ltd Métodos de tratamento de hipertensão arterial pulmonar
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
WO2021152060A1 (fr) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Composition de sélexipag à libération contrôlée
EP4100013A1 (fr) 2020-02-03 2022-12-14 Actelion Pharmaceuticals Ltd Méthodes de traitement et d'évaluation de l'hypertension artérielle pulmonaire au moyen de sélexipag
WO2022106621A1 (fr) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Sélexipag destiné à être utilisé par l'intermédiaire d'une administration intracôlon
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
JP7010404B1 (ja) 2021-03-31 2022-02-10 日本新薬株式会社 歩行障害治療剤
TW202304444A (zh) 2021-03-31 2023-02-01 日商日本新藥股份有限公司 步行障礙治療劑
WO2022238375A1 (fr) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Méthodes de traitement de l'hypertension pulmonaire
CN113968824B (zh) * 2021-11-29 2024-01-19 郑州大学 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
AU2023222747A1 (en) 2022-02-15 2024-08-22 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
CN117304174A (zh) * 2022-06-20 2023-12-29 四川轻化工大学 一种5,6-二苯基吡嗪-2-氮杂环类化合物及其制备方法和应用
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024131672A1 (fr) * 2022-12-20 2024-06-27 长风药业股份有限公司 Dérivé de diphényl pyrazine, son procédé de préparation et son utilisation
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
CN116143704B (zh) * 2023-02-27 2025-05-27 广州楷石生物科技有限公司 司来帕格体内代谢物的一氧化氮供体药物
TW202444370A (zh) 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡衍生物之醫藥組成物
KR20250008015A (ko) 2023-07-06 2025-01-14 재단법인대구경북과학기술원 셀렉시팍을 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학 조성물
CN117510465A (zh) * 2023-11-03 2024-02-06 四川轻化工大学 一种5,6-二苯基吡嗪-2-哌啶类化合物及其制备方法和应用
CN118955410B (zh) * 2023-12-27 2025-08-26 石家庄四药有限公司 二苯基吡嗪类化合物及其组合物、应用和制备方法
CN119033791A (zh) * 2023-12-27 2024-11-29 石家庄四药有限公司 一种包含pgi2受体激动剂的药物组合物及其用途
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用
WO2025196095A1 (fr) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable pour le traitement de l'hypertension pulmonaire
CN118750498B (zh) * 2024-07-22 2025-07-08 石家庄四药有限公司 一种包括化合物syn045的药物组合物、制剂及制备方法
CN118903146B (zh) * 2024-07-22 2025-09-12 石家庄四药有限公司 包括化合物syn045的药物组合物、制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416491A (en) 1977-05-17 1979-02-07 Diamond Shamrock Corp Substituted 1*2*44triazines having pharmacological action
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JP3169413B2 (ja) * 1992-01-31 2001-05-28 エーザイ株式会社 イミダゾール誘導体
JPH0733752A (ja) * 1993-07-16 1995-02-03 Sankyo Co Ltd ジフェニルピラジン誘導体及び除草剤
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist

Also Published As

Publication number Publication date
DK1400518T3 (da) 2007-03-26
JPWO2002088084A1 (ja) 2004-09-09
RU2283835C2 (ru) 2006-09-20
RU2003134190A (ru) 2005-06-10
BRPI0209249B8 (pt) 2021-05-25
MXPA03009800A (es) 2004-01-29
RU2283835C3 (ru) 2021-02-15
JP4479152B2 (ja) 2010-06-09
NL300836I2 (fr) 2016-11-16
BE2016C051I2 (fr) 2021-07-19
CA2445344C (fr) 2011-07-26
LU93266I2 (fr) 2016-12-19
BR0209249A (pt) 2004-06-08
EP1400518A4 (fr) 2005-04-20
DE60217674D1 (de) 2007-03-08
KR100921760B1 (ko) 2009-10-15
BRPI0209249B1 (pt) 2016-04-26
EP1400518B1 (fr) 2007-01-17
EP1400518A1 (fr) 2004-03-24
DE60217674T2 (de) 2007-10-11
US20040102436A1 (en) 2004-05-27
PT1400518E (pt) 2007-03-30
CA2445344A1 (fr) 2002-11-07
KR20040015174A (ko) 2004-02-18
TWI316055B (fr) 2009-10-21
ES2276931T3 (es) 2007-07-01
CN1301973C (zh) 2007-02-28
US7205302B2 (en) 2007-04-17
CN1516690A (zh) 2004-07-28
FR16C0042I1 (fr) 2016-12-09
WO2002088084A1 (fr) 2002-11-07

Similar Documents

Publication Publication Date Title
FR16C0042I2 (fr) Derives de composes heterocycliques et medicaments
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
PT1221918E (pt) Administracao de drogas sub-tenon
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
FR2847253B1 (fr) Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
IL160714A0 (en) Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
AU2002331391A1 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
LTC1345910I2 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EP0948341A4 (fr) Derives de medicaments phospholipidiques
NO20013945D0 (no) Fremstilling av isoflavonderivater
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
BRPI0209720A2 (pt) dosagem e embalagem de medicação com liberação controlada
NO20020531D0 (no) Beta-carbolin medikament produkter
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
NO20022021D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler
IL161854A0 (en) Heterocyclic derivatives of glycinamide and their medical use
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
IL159085A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
ATE362915T1 (de) Heterocyclische derivate und arzneistoffe
DE60139306D1 (de) N-deacetylthiocolchin-derivate und diese enthaltende arzneimittel
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
HUP0204560A3 (en) Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use